𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease

✍ Scribed by Stephan R. Vavricka; Sabrina M. Spigaglia; Gerhard Rogler; Valérie Pittet; Pierre Michetti; Christian Felley; Christian Mottet; Christian P. Braegger; Daniela Rogler; Alex Straumann; Peter Bauerfeind; Michael Fried; Alain M. Schoepfer; the Swiss IBD Cohort Study Group


Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
808 KB
Volume
18
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Background:

The diagnosis of inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), continues to present difficulties due to unspecific symptoms and limited test accuracies. We aimed to determine the diagnostic delay (time from first symptoms to IBD diagnosis) and to identify associated risk factors.

Methods: A total of 1591 IBD patients (932 CD, 625 UC, 34 indeterminate colitis) from the Swiss IBD cohort study (SIBDCS) were evaluated.

The SIBDCS collects data on a large sample of IBD patients from hospitals and private practice across Switzerland through physician and patient questionnaires. The primary outcome measure was diagnostic delay.

Results: Diagnostic delay in CD patients was significantly longer compared to UC patients (median 9 versus 4 months, P < 0.001). Seventyfive percent of CD patients were diagnosed within 24 months compared to 12 months for UC and 6 months for IC patients. Multivariate logistic regression identified age <40 years at diagnosis (odds ratio [OR] 2.15, P ¼ 0.010) and ileal disease (OR 1.69, P ¼ 0.025) as independent risk factors for long diagnostic delay in CD (>24 months). In UC patients, nonsteroidal antiinflammatory drug (NSAID intake (OR 1.75, P ¼ 0.093) and male gender (OR 0.59, P ¼ 0.079) were associated with long diagnostic delay (>12 months).

Conclusions: Whereas the median delay for diagnosing CD, UC, and IC seems to be acceptable, there exists a long delay in a considerable proportion of CD patients. More public awareness work needs to be done in order to reduce patient and doctor delays in this target population.


📜 SIMILAR VOLUMES


Incidence and risk factors for gallstone
✍ Fabrizio Parente; Luca Pastore; Stefano Bargiggia; Claudia Cucino; Salvatore Gre 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

The risk for gallstones (GD) in inflammatory bowel diseases and the factors responsible for this complication have not been well established. We studied the incidence of GD in a cohort of Crohn's disease (CD) and ulcerative colitis (UC) patients and investigated the related risk factors. A case-cont

Prevalence of hepatitis B and C and risk
✍ Jean-Baptiste Chevaux; Abdelbasset Nani; Abderrahim Oussalah; Véronique Venard; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: Data regarding the prevalence of hepatitis c (hcv) and hepatitis b (hbv) in inflammatory bowel disease (ibd) patients are conflicting. ## Methods: In all, 315 ibd (252 crohn's disease [cd] and 63 ulcerative colitis [uc]) patients were consecutively recruited between june 2005 and m

Educational level and occupation as risk
✍ Xinjun Li; Jan Sundquist; Kristina Sundquist 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Background: The aim of this study was to investigate possible associations between educational level, occupation, and hospitalization for inflammatory bowel disease. ## Methods: A nationwide database was constructed by linking the swedish census to the hospital discharge register in order to o

Increased risk of vancomycin-resistant e
✍ Geoffrey C. Nguyen; Wesley Leung; Adam V. Weizman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Background: Vancomycin-resistant Enterococcus (VRE) infection has become an increasingly common hospital-acquired infection in U.S. hospitals. Patients with inflammatory bowel disease (IBD) frequently require hospitalization and therefore may be at increased risk of nosocomial infections. Methods:

Unfractionated or low molecular weight h
✍ Nilesh Chande; John K. MacDonald; Josh J. Wang; John W.D. McDonald 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

## Background: We aimed to systematically review the efficacy of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for remission induction in patients with ulcerative colitis (UC). Methods: A literature search to April 2011 was performed to identify all randomized trials studyi